Johnson & Johnson Reports Strong Q3 Results Despite Medtech Challenges
Johnson & Johnson reported strong third-quarter results with revenue rising to $25.4 billion, a 5.9% increase year-over-year. Adjusted earnings per share were slightly down at $2.59 due primarily to acquisition impacts rather than operational issues. The pharmaceutical segment was the standout performer, driven by products like Darzalex and Tremfya, which saw significant sales growth. However, Johnson & Johnson's medtech business underperformed expectations with revenue of $8.6 billion, up only 2.5% year-over-year. This weakness contributed to a post-earnings stock dip as investors reacted negatively to the segment’s performance and ongoing challenges in its cardiovascular unit abroad due to safety concerns around Impella heart pumps. Despite these issues, Johnson & Johnson raised its full-year sales guidance slightly for fiscal 2026, reflecting confidence in continued pharmaceutical growth. The company is also conducting a clinical trial that could help address medtech headwinds.
Tickers: $JNJ
Topics: earnings pharmaceuticals revenue growth